title: Evaluation of the Genetic Systems Corp. Integra HIV-1 Pageblot system.
abstract: The Genetic Systems Corp. Integra HIV-1 Pageblot system was evaluated as a supplementary assay to confirm the presence of antibodies to human immunodeficiency virus type 1 in 57 specimens from individuals at high risk of infection with the virus. Forty-one specimens identified as reactive in the Genetic Systems Integra HIV-1 Pageblot system were likewise identified as reactive in a U.S. Food and Drug Administration-licensed (Biotech/Dupont) Western blot (immunoblot). Six specimens identified as indeterminate in either or both immunoblot assays were all identified as nonreactive in a U.S. Food and Drug Administration-licensed enzyme immunoassay with recombinant antigens.
authors.affiliation: Department of Microbiology, Cleveland Clinic Foundation, Ohio 44195.
authors.forename: C A
authors.initials: CA
authors.lastname: Starkey
authors.forename: B
authors.initials: B
authors.lastname: Yen-Lieberman
authors.forename: M R
authors.initials: MR
authors.lastname: Proffitt
mesh_terms: D015153:Blotting, Western / Q000379:methods* / Q000706:statistics & numerical data; D005069:Evaluation Studies as Topic; D015483:HIV Antibodies / Q000097:blood*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D012680:Sensitivity and Specificity
chemical_list: D015483:HIV Antibodies